Sai Life Sciences Limited, a leading contract research, development, and manufacturing organization (CRDMO), has inaugurated its dedicated Peptide Research Center at its integrated R&D campus in Hyderabad, India. The new center is set to cater to the growing demand for complex peptide synthesis and conjugation, driven by the pharmaceutical industry’s shift from small molecules to next-generation therapeutic modalities.
Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, highlighted the company’s proactive expansion into advanced peptide capabilities, stating, “Our new Peptide Research Center reflects this commitment—designed to meet the growing demand for complex peptide synthesis and conjugation. With this investment, we reinforce our role as a trusted partner in advancing next-generation therapeutics.”
The facility is equipped with cutting-edge automation, robotics, liquid handling, and high-throughput systems, enhancing scalability and efficiency in developing peptide therapeutics. It will offer comprehensive services from peptide synthesis and discovery to advanced modalities, supporting biotech and innovator pharma clients globally.
Maneesh Pingle, Head of Discovery Services, emphasized the rising global interest in peptide-based drugs, citing their high specificity, biocompatibility, and lower off-target effects. He added that the company’s seasoned scientific team and the integration of this new facility into Sai Life Sciences’ broader discovery services—spanning medicinal chemistry, biology, DMPK, and toxicology—will help accelerate timelines and improve success rates in drug discovery.
This strategic addition to the company’s infrastructure underscores Sai Life Sciences’ long-term commitment to supporting innovation in emerging therapeutic spaces and enhancing India’s presence in global life sciences R&D.
